The Sun Pharma Imatinib Patient Assistance Program is offered to allow qualified patients to obtain free medication. It is not a government program or an insurance plan. If a patient qualifies, they may receive free Imatinib medication each month through July 2016 as long as they continue to meet the program requirements.
Full Answer
Where can I buy imatinib?
Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide. Imatinib offers may be in the form of a printable coupon, rebate, savings or copay card, trial offer, or free samples.
How do I contact Sun Pharma products?
Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients in more than 100 countries worldwide. If you have any questions about Sun Pharma Products, please contact Sun Pharma Customer Service at 800-818-4555.
Who is Sunsun Pharma?
Sun Pharma is the fourth largest global specialty generic pharmaceutical company in the world, with revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients in more than 100 countries worldwide.
What is imatinib (Gleevec)?
Imatinib is a member of the BCR-ABL tyrosine kinase inhibitors drug class and is commonly used for Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, and others. Brand names for imatinib include Gleevec .
How much does imatinib cost?from drugs.com
Imatinib Prices. The cost for imatinib oral tablet 400 mg is around $102 for a supply of 30 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is PAF in Novartis?from hematology.org
The Novartis Patient Assistance Foundation (PAF) can help patients acquire high cost drugs either for free or at reduced process. For help acquiring imatinib, visit the online enrollment page, select imatinib, and fill in the required information.
Who owns Teva Pharmaceuticals?from tevapharm.com
Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the leading pharmaceutical companies in the world.
Does Patient Access Network Foundation offer co-pay assistance?from hematology.org
The Patient Access Network Foundation also offers co-pay assistance for patients needing imatinib. Please read the application instructions , and then follow the prompts on the online application .
Is Gleevec a registered trademark?from tevapharm.com
1 GLEEVEC ® is a registered trademark of Novartis Oncology.
How much does imatinib cost?
Imatinib Prices. The cost for imatinib oral tablet 400 mg is around $102 for a supply of 30 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is imatinib used for?
Imatinib is a member of the BCR-ABL tyrosine kinase inhibitors drug class and is commonly used for Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, and others.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
What is the effect of hepatic impairment on imatinib?from accessdata.fda.gov
The effect of hepatic impairment on the pharmacokinetics of both imatinib and its major metabolite, CGP74588, was assessed in 84 cancer patients with varying degrees of hepatic impairment (Table 11) at imatinib doses ranging from 100-800 mg. Exposure to both imatinib and CGP74588 was comparable between each of the mildly and moderately hepatically-impaired groups and the normal group .Patients with severe hepatic impairment tend to have higher exposure to both imatinib and its metabolite than patients with normal hepatic function. At steady state, the mean Cmax/dose and AUC/dose for imatinib increased by about 63% and 45%, respectively, in patients with severe hepatic impairment compared to patients with normal hepatic function. The mean Cmax/dose and AUC/dose for CGP74588 increased by about 56% and 55%, respectively, in patients with severe hepatic impairment compared to patients with normal hepatic function [see Dosage and Administration (2.10)].
How long does it take for imatinib to be absorbed?from drugs.com
As in adult patients, Imatinib was rapidly absorbed after oral administration in pediatric patients, with a C max of 2 to 4 hours. Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs. 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults). Dosing in children at both 260 mg/m 2 and 340 mg/m 2 achieved an AUC similar to the 400 mg dose in adults. The comparison of AUC on Day 8 vs. Day 1 at 260 mg/m 2 and 340 mg/m 2 dose levels revealed a 1.5- and 2.2-fold drug accumulation, respectively, after repeated once-daily dosing. Mean Imatinib AUC did not increase proportionally with increasing dose.
How old is the median age for imatinib mesylate?from drugs.com
Median age was 46 years in the Imatinib mesylate group and 47 years in both nilotinib groups, with 12%, 13%, and 10% of patients greater than or equal to 65 years of age in Imatinib mesylate 400 mg once-daily, nilotinib 300 mg twice daily and nilotinib 400 mg twice daily treatment groups, respectively.
What is imatinib mesylate?from drugs.com
Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients.
How long after stopping imatinib mesylate?from drugs.com
Advise female patients of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using Imatinib mesylate during treatment and for fourteen days after stopping treatment with Imatinib mesylate [see Use in Specific Populations ( 8.1 )] .
Why was Imatinib mesylate discontinued?from drugs.com
Imatinib mesylate was discontinued due to drug-related adverse reactions in 2.4% of patients receiving Imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing Imatinib mesylate versus IFN+Ara-C, and in 12.5% of patients receiving Imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing Imatinib mesylate and nilotinib. Imatinib mesylate was discontinued due to drug-related adverse reactions in 4% of patients in chronic phase after failure of interferon- alpha therapy, in 4% of patients in accelerated phase and in 5% of patients in blast crisis.#N#The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash (Table 2 and Table 3 for newly diagnosed CML, Table 4 for other CML patients). Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Imatinib mesylate [ see Dosage and Administration ( 2.13) ]. The frequency of severe superficial edema was 1.5% to 6%.#N#A variety of adverse reactions represent local or general fluid retention, including pleural effusion, ascites, pulmonary edema and rapid weight gain with or without superficial edema. These reactions appear to be dose related, were more common in the blast crisis and accelerated phase studies (where the dose was 600 mg/day), and are more common in the elderly. These reactions were usually managed by interrupting Imatinib mesylate treatment and using diuretics or other appropriate supportive care measures. These reactions may be serious or life threatening.#N#Adverse reactions, regardless of relationship to study drug, that were reported in at least 10% of the Imatinib mesylate treated patients are shown in Tables 2, 3, and 4.
What enzymes are involved in the metabolism of imatinib?from drugs.com
CYP3A4 is the major enzyme responsible for metabolism of Imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to the parent Imatinib. The plasma AUC for this metabolite is about 15% of the AUC for Imatinib. The plasma protein binding of N-demethylated metabolite CGP74588 is similar to that of the parent compound. Human liver microsome studies demonstrated that Imatinib mesylate is a potent competitive inhibitor of CYP2C9, CYP2D6, and CYP3A4/5 with Ki values of 27, 7.5, and 8 µM, respectively.#N#Excretion
How much does imatinib cost?from drugs.com
Imatinib Prices. The cost for imatinib oral tablet 400 mg is around $102 for a supply of 30 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is PAF in Novartis?from hematology.org
The Novartis Patient Assistance Foundation (PAF) can help patients acquire high cost drugs either for free or at reduced process. For help acquiring imatinib, visit the online enrollment page, select imatinib, and fill in the required information.
Who owns Teva Pharmaceuticals?from tevapharm.com
Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the leading pharmaceutical companies in the world.
Does Patient Access Network Foundation offer co-pay assistance?from hematology.org
The Patient Access Network Foundation also offers co-pay assistance for patients needing imatinib. Please read the application instructions , and then follow the prompts on the online application .
Is Gleevec a registered trademark?from tevapharm.com
1 GLEEVEC ® is a registered trademark of Novartis Oncology.